Cited by 468Heart Failure Treatment and ManagementChronic Disease Management StrategiesCardiovascular Function and Risk Factors

Co-Morbidities in Patients with Heart Failure: An Analysis of the European Heart Failure Pilot Survey

Open access
van Deursen, Vincent M., Urso, Renato, Laroche, Cecile, Damman, Kevin, Dahlström, Ulf, Tavazzi, Luigi, Maggioni, Aldo P., Voors, Adriaan A.·2014·European Journal of Heart Failure

Abstract

Aims: Co-morbidities frequently accompany heart failure (HF), contributing to increased morbidity and mortality, and an impairment of quality of life. We assessed the prevalence, determinants, regional variation, and prognostic implications of co-morbidities in patients with chronic HF in Europe. Methods and results: A total of 3226 European outpatients with chronic HF were included in this analysis of the European Society of Cardiology (ESC) Heart Failure Pilot Survey. The following co-morbidities were considered: diabetes, hyper- and hypothyroidism, stroke, COPD, sleep apnoea, chronic kidney disease (CKD), and anaemia. Prognostic implications of co-morbidities were evaluated using population attributable risks (PARs), and patients were divided into geographic regions. Clinical endpoints were all-cause mortality and HF hospitalization. The majority of patients (74%) had a least one co-morbidity, the most prevalent being CKD (41%), anaemia (29%), and diabetes (29%). Co-morbidities were independently associated with higher age (P < 0.001), higher NYHA functional class (P < 0.001), ischaemic aetiology of HF (P < 0.001), higher heart rate (P = 0.011), history of hypertension (P < 0.001), and AF (P < 0.001). Only diabetes, CKD, and anaemia were independently associated with a higher risk of mortality and/or HF hospitalization. There were marked regional differences in prevalence and prognostic implications of co-morbidities. Prognostic implications of co-morbidities (PARs) were: CKD = 41%, anaemia = 37%, diabetes = 14%, COPD = 10%, and <10% for all other co-morbidities. Conclusion: In this pilot survey, co-morbidities are prevalent in patients with chronic HF and are related to the severity of the disease. The presence of diabetes, CKD, and anaemia was independently related to increased mortality and HF hospitalization, with the highest PAR for CKD and anaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.30

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Schuett et al. independently validated the association of TMAO with poor heart failure outcomes specifically in heart failure with reduced ejection fraction patients.

    “Most recently, Schuett et al. independently validated the association of TMAO with poor heart failure outcomes, specifically in heart failure with reduced ejection fraction patients184.”

    From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [184]

  • TMAO was able to better predict outcomes compared to BNP in HFrEF patients after adjusting for traditional risk factors and renal function.

    “Moreover, they found that TMAO was able to better predict outcomes compared to BNP in this population, after adjusting for traditional risk factors and renal function.”

    From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [184]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythro- poietin in cardiovascular diseases. Eur Heart J 2004;25:285-291.
  2. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-678.
  3. Voors AA, van der Horst IC. Diabetes: a driver for heart failure. Heart 2011;97:774-780.

Cited by

Sorted by citations

Authors
van Deursen, V. M., Urso, R., Laroche, C., Damman, K., Dahlström, U., Tavazzi, L., Maggioni, A. P., & Voors, A. A.
Affiliations
  • Department of Cardiology, University of Groningen , Groningen ,
  • University of Siena (IT)
  • EORP Department, ESC , Sophie Antipolis ,
  • University of Groningen (NL)
  • Linköping University Hospital (SE)
  • Maria Cecilia Hospital (IT)
  • Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
Corresponding author
Voors, Adriaan A.
Venue
European Journal of Heart Failure
Published
2013-12-19
Volume
16
Issue
1
Pages
103-111
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2151341839
Cited by
468
References
44
Citations by year
2026: 14 · 2025: 31 · 2024: 29 · 2023: 46 · 2022: 44 · 2021: 45 · 2020: 50 · 2019: 41 · 2018: 48 · 2017: 39 · 2016: 41 · 2015: 24 · 2014: 13 · 2013: 1
FWCI
17.89
Type
journal article
Language
en
Open access
Locations
  • European Journal of Heart Failure (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • Amgen
  • Sanofi
  • Boston Scientific Corporation
  • Servier
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
heart failure, comorbidities, chronic kidney disease, anemia, diabetes mellitus, all-cause mortality, heart failure hospitalization, population attributable risk, regional variation, prognosis
MeSH terms
Anemia, Diabetes Mellitus, Europe, Heart Failure, Humans, Outpatients, Pilot Projects, Prospective Studies, Registries, Societies, Medical, Comorbidity, Prevalence, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review